



## Review

# Molecular recognition in the human immunodeficiency virus capsid and antiviral design

Rebeca Bocanegra<sup>1</sup>, Alicia Rodríguez-Huete, Miguel Ángel Fuertes, Marta del Álamo<sup>1</sup>,  
Mauricio G. Mateu\*

Centro de Biología Molecular "Severo Ochoa" (CSIC-UAM), Universidad Autónoma de Madrid, 28049 Madrid, Spain

## ARTICLE INFO

## Article history:

Available online 21 June 2012

## Keywords:

Human immunodeficiency virus  
Capsid  
Molecular recognition  
Peptide  
Interfacial inhibitor  
Antiviral agent

## ABSTRACT

Many compounds able to interfere with HIV-1 infection have been identified; some 25 of them have been approved for clinical use. Current anti-HIV-1 therapy involves the use of drug cocktails, which reduces the probability of virus escape. However, many issues remain, including drug toxicity and the emergence of drug-resistant mutant viruses, even in treated patients. Therefore, there is a constant need for the development of new anti-HIV-1 agents targeting other molecules in the viral cycle. The capsid protein CA plays a key role in many molecular recognition events during HIV-1 morphogenesis and uncoating, and is eliciting increased interest as a promising target for antiviral intervention. This article provides a structure-based, integrated review on the CA-binding small molecules and peptides identified to date, and their effects on virus capsid assembly and stability, with emphasis on recent results not previously reviewed. As a complement, we present novel experimental results on the development and proof-of-concept application of a combinatorial approach to study molecular recognition in CA and its inhibition by peptide compounds.

© 2012 Elsevier B.V. All rights reserved.

## Contents

1. Introduction .....	389
2. Molecular recognition in the HIV-1 capsid .....	390
2.1. The capsid protein CA .....	390
2.2. Structural organization of the immature HIV-1 capsid .....	390
2.3. Structural organization of the mature HIV-1 capsid .....	393
2.3.1. The mature capsid lattice .....	393
2.3.2. The CTD–CTD interface .....	393
2.3.3. The NTD–NTD interface .....	393
2.3.4. The NTD–CTD interface .....	394
2.4. Conformational rearrangements in the HIV-1 capsid .....	394
3. Targeting protein–protein interfaces in antiviral research .....	395
3.1. Using small organic compounds to inhibit protein–protein recognition .....	395
3.2. Using peptides to inhibit protein–protein recognition .....	396
4. Capsid protein-binding organic compounds as HIV-1 inhibitors .....	396
4.1. $\alpha$ -Hydroxyglycineamide .....	396
4.2. CAP-1 and related organic compounds .....	396
4.2.1. CAP-1 .....	396
4.2.2. CAP-1 derivatives .....	396
4.3. Acylhydrazones and other organic compounds targeting CA polymerization, and acylhydrazone derivatives .....	396
4.4. Benzodiazepines and benzimidazoles targeting CA polymerization .....	397

\* Corresponding author at: Centro de Biología Molecular "Severo Ochoa", Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain.  
Tel.: +34 91 1964575; fax: +34 91 1964420.

E-mail address: [mgarcia@cbm.uam.es](mailto:mgarcia@cbm.uam.es) (M.G. Mateu).

<sup>1</sup> Present address: Centro Nacional de Biotecnología (CSIC), Universidad Autónoma de Madrid, 28049 Madrid, Spain.

4.5.	PF-3450074 and related organic compounds .....	397
4.6.	Organic compounds targeting the CAI site in CTD .....	398
4.7.	Organic dendrimers .....	398
5.	Capsid protein-binding peptides as HIV-1 inhibitors .....	398
5.1.	CA peptide PAATLEEMMTA .....	398
5.2.	CA peptide IPVGEIYKRW .....	398
5.3.	CAI peptide and derivatives .....	398
5.3.1.	CAI .....	398
5.3.2.	NYAD-1 and other CAI-derived stapled peptides .....	399
5.4.	CAC1 peptide and derivatives .....	399
5.4.1.	CAC1 and its CAC1M derivative .....	399
5.4.2.	Shortened CAC1 derivatives .....	399
5.4.3.	NYAD-201 and other CAC1-derived stapled peptides .....	399
5.5.	H8 peptide .....	400
5.6.	Peptide cocktails .....	400
5.7.	Recombinant ankyrin AnkGAG1D4 .....	400
6.	Inhibition of HIV-1 capsid assembly in a macromolecularly crowded environment .....	401
7.	An integrated view on inhibitors targeting the HIV-1 capsid .....	401
7.1.	A summary of antiviral strategies targeting CA, the compounds identified, and their binding sites .....	401
7.2.	Small molecules to inhibit HIV-1 capsid assembly .....	402
7.3.	Peptides to inhibit HIV-1 capsid assembly .....	402
7.4.	HIV-1 resistance to inhibitors of capsid assembly .....	403
8.	A combinatorial methodology to study CA dimerization and its inhibition .....	403
8.1.	Introduction .....	403
8.2.	Materials and methods .....	404
8.2.1.	Recombinant plasmids and CTD combinatorialization .....	404
8.2.2.	Selection of CTD mutants by colony screening .....	404
8.2.3.	Protein expression and purification .....	404
8.2.4.	Circular dichroism and fluorescence spectroscopy .....	404
8.2.5.	Determination of affinity constants by analytical gel filtration chromatography .....	404
8.2.6.	Capsid assembly inhibition assay .....	404
8.3.	Results .....	405
8.3.1.	A colony screening assay to identify CTD variants of high affinity for CA .....	405
8.3.2.	CTD residues chosen for combinatorialization, and selection of strongest CA binders from a combinatorial library .....	405
8.3.3.	Biophysical characterization of CTD-19b .....	405
8.3.4.	CTD-19b as an inhibitor of mature HIV-1 capsid assembly <i>in vitro</i> .....	407
8.4.	Discussion .....	407
9.	Conclusions .....	407
	Acknowledgments .....	407
	References .....	407

## 1. Introduction

The biological cycle of any virus involves a complex chain of molecular recognition events between viral proteins and nucleic acids, and between viral and cellular macromolecules. In principle, any small molecule capable of interfering with any one of those reactions constitutes a potential antiviral drug. Thus, many targets and strategies for antiviral intervention exist (De Clercq, 2002; Kräusslich and Bartenschlager, 2009); most of them are essentially unexplored.

Human immunodeficiency virus type 1 (HIV-1) has been the major target of antiviral research to date. Many compounds able to interfere with HIV-1 infection have been identified; some 25 of them have been approved for clinical use, and others are in clinical trials (De Clercq, 2004; Broder, 2010; Ghosh et al., 2011). Life expectancy for acquired immunodeficiency syndrome (AIDS) patients was extremely short before the first antiretroviral drug, zidovudine, was introduced in 1987. Still, administering a single drug soon proved inadequate, due to the frequent emergence in the patients of drug-resistant virus variants. HIV-1 and other RNA virus populations are quasispecies formed by non-identical individuals that result from error-prone replication, and may evolve very rapidly (Domingo, 1989; Domingo et al., 2001). High mutation frequencies, high replication rates and large population sizes lead together to a high probability of finding in an infected host one or more individual viruses that carry the mutation (or

combination of mutations) required to escape from the action of a single antiviral drug.

Current highly active antiretroviral therapies (HAART) (Barbaro et al., 2005) involve the use of cocktails of (usually) three anti-HIV-1 drugs. HAART reduces drastically the probability of virus escape because enough mutations must accumulate in a single virus genome to impair the action of different drugs that act through different mechanisms on different targets. Introduction of HAART around 1996 was decisive in turning HIV-1 infection from a lethal disease into a chronic disease with long life expectancy and improved quality of life for patients receiving adequate treatment. However, many critical issues still remain, including drug toxicity, poor patient compliance, and the emergence of drug-resistant virus variants, even in HAART-treated patients. Therefore, there is a constant need for new anti-HIV-1 drugs targeting other molecules and molecular recognition events in the viral cycle.

Most of the approved anti-HIV drugs target the HIV-1 enzymes reverse transcriptase (RT) or protease (PR). A few are directed against the HIV-1 integrase (IN), virus entry (by targeting either receptor/coreceptor recognition or membrane fusion; Melby and Westby, 2009), or virion maturation (Salzwedel et al., 2007; Adamson et al., 2009). The structural proteins nucleocapsid (NC) and capsid (CA) are, however, eliciting increased interest as promising targets for anti-HIV-1 intervention. Interest in NC and CA for antiviral research has been greatly stimulated by recent advances in the understanding of nucleocapsid and capsid structure and

Download English Version:

<https://daneshyari.com/en/article/3428651>

Download Persian Version:

<https://daneshyari.com/article/3428651>

[Daneshyari.com](https://daneshyari.com)